Table 1.
Mean ± SEM active and inactive nose-pokes after training and extinction
| Active: | Acq10 |
E1 |
E4 |
Inactive: | Acq10 |
E1 |
E4 |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SEM | Mean | SEM | Mean | SEM | Mean | SEM | Mean | SEM | Mean | SEM | ||
| RNAscope | |||||||||||||
| ABA | 56.7 | 2.0 | 33.7 | 4.2 | 6.8 | 1.2 | 9.9 | 1.1 | 3.9 | 1.2 | 1.7 | 0.3 | |
| ABB | 61.8 | 1.0 | 31.2 | 4.7 | 11.3 | 5.0 | 14.5 | 0.5 | 3.4 | 0.8 | 2.1 | 2.9 | |
| ABO | 78.5 | 0.5 | 34.0 | 2.5 | 6.8 | 2.0 | 8.8 | 0.5 | 5.2 | 0.3 | 1.2 | 0.6 | |
| VPGAD1 Inhibition | |||||||||||||
| GAD-CRE− | 161.5 | 13.0 | 30.0 | 4.0 | 7.6 | 1.4 | 1.8 | 0.7 | 4.3 | 0.8 | 0.9 | 0.5 | |
| GAD-CRE+ | 147.9 | 10.1 | 35.0 | 5.6 | 4.4 | 1.3 | 2.1 | 0.7 | 3.7 | 1.0 | 0.9 | 0.7 | |
| VPPV Inhibition | |||||||||||||
| PV-CRE− | 72.9 | 17.8 | 41.9 | 10.0 | 6.1 | 1.3 | 0.6 | 0.4 | 3.8 | 1.0 | 1.3 | 0.6 | |
| PV-CRE+ | 77.1 | 17.7 | 46.1 | 6.9 | 8.1 | 3.6 | 0.8 | 0.3 | 2.9 | 0.7 | 1.0 | 0.7 | |
| VP to LH Tracing VP-LH tracing | |||||||||||||
| ABA | 106.4 | 19.3 | 29.6 | 6.3 | 5.6 | 0.4 | 2.2 | 0.6 | 6.2 | 2.5 | 3.4 | 1.5 | |
| ABB | 88.0 | 17.0 | 34.2 | 3.9 | 6.8 | 1.7 | 1.8 | 0.7 | 4.5 | 1.1 | 3.5 | 0.9 | |
| ABO | 117.3 | 37.6 | 38.3 | 3.8 | 8.3 | 1.2 | 1.0 | 0.5 | 3.3 | 1.0 | 1.7 | 0.3 | |
| VPGAD1 to LH Inhibition | |||||||||||||
| GAD1-CRE−:LH Contra | 72.9 | 11.5 | 75.1 | 46.5 | 8.6 | 2.5 | 1.3 | 0.3 | 3.9 | 0.5 | 1.3 | 0.6 | |
| GAD1-CRE+:LH Ipsi | 68.7 | 14.6 | 38.3 | 5.4 | 7.4 | 1.7 | 1.1 | 0.6 | 3 | 0.7 | 1.7 | 0.4 | |
| GAD1-CRE+:LH Contra | 65.1 | 10.9 | 56.5 | 13.2 | 12 | 2.5 | 0.9 | 0.4 | 4.4 | 0.9 | 1.4 | 0.4 | |
| VPGAD1 to VTA Inhibition | |||||||||||||
| GAD1-CRE−:VTA | 49.7 | 6.7 | 26.3 | 3.1 | 10.6 | 1.6 | 0.71 | 0.3 | 2.6 | 0.8 | 3.1 | 1.2 | |
| GAD1-CRE+:VTA | 75.1 | 26.9 | 34 | 4.4 | 21.9 | 4.4 | 1 | 0.5 | 4.3 | 1.3 | 3.3 | 0.6 | |
| VPPV to LH Inhibition | |||||||||||||
| PV-CRE−:LH Contra | 82.4 | 20.5 | 49.0 | 10.6 | 9.1 | 1.3 | 1.7 | 0.7 | 3.7 | 0.9 | 2.3 | 0.7 | |
| PV-CRE+:LH Ipsi | 74.2 | 8.0 | 39.8 | 7.7 | 14.5 | 3.9 | 1.5 | 0.7 | 4.8 | 1.6 | 2.3 | 1.1 | |
| PV-CRE+:LH Conta | 64.4 | 7.8 | 57.4 | 7.8 | 10.4 | 3.6 | 1.4 | 0.6 | 5.4 | 1.5 | 1.7 | 0.8 | |
| VPPV to VTA Inhibition | |||||||||||||
| PV-CRE−:VTA Contra | 106.1 | 12.8 | 29.3 | 5.0 | 7.3 | 1.5 | 0.6 | 0.3 | 3.4 | 1.4 | 1.9 | 0.7 | |
| PV-CRE+:VTA Ipsi | 160.2 | 48.8 | 25.2 | 2.6 | 14.2 | 3.6 | 2.3 | 0.8 | 4.7 | 1.3 | 1.8 | 0.5 | |
| PV-CRE+:VTA Contra | 84.6 | 16.6 | 22.9 | 5.4 | 6.4 | 0.8 | 1.2 | 0.6 | 3.8 | 0.7 | 2.1 | 0.7 | |